. . . . . . . . . "farxiga dapagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus see clinical studies 14 farxiga is a sodium glucose cotransporter 2 sglt2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1 limitation of use 1 1 farxiga is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis" . . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "MtoROUE0AN4YKyXgqd3AtbBleIoLMWpFVEtmRggc8rDCDAUWmsOzMu4wTZcW3fnMsdwCKhNuRteHPG2r+tmel7PwjbE6ULUCd0ZW1brf/xqB9aX2gymtc/hGvhTOlhKlAQJYH97kbEUNWXG0HbfXmR8QFErRaEVWzQrpSQHGECw=" . . "2021-06-12T14:46:04.945+02:00"^^ . . . . .